docGlobal Anti-Infective Vaccines Market
download 
Report Transcription
Global Anti-Infective Vaccines Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016 – 2026 Future Market Insights www.futuremarketinsights.com sales@futuremarketinsights.com Report Description Report Description Rapidly spreading infectious diseases such as tuberculosis, malaria, Hepatitis B, HIV/AIDS, influenza and others are becoming major concern to the society and the healthcare professionals as they are majorly contributing to worldwide causes of death and presenting huge burden on healthcare systems. Infectious diseases are treated with category of drugs including antivirals and anti-infective agents along with adjunct therapy of immune system boosters. Anti-infective vaccines are the most powerful health measure taken by the healthcare systems to prevent the rapidly spreading infectious diseases. Infectious diseases being a substantial health threat, numerous companies are trying to innovate novel anti-infective vaccines to combat patient burden on medical managements. Anti-infective vaccines for the prophylaxis of diseases such as influenza (Fluarix, Fluzone, FluMist), hepatitis (Recombivax HB, Havrix, Engerix-B), malaria (RTS,S), polio (IPOL), tuberculosis (BCG) are readily available in market. Anti- infective vaccines for some infectious diseases such as polio and tetanus are given to child after birth under the national immunization programs. Anti-infective vaccines Market: Drivers and Restraints Increasing incidence of infectious diseases, incidence of new emerging diseases, bioterrorism and resistance to existing anti-infective therapies are the major drivers for the growth of global anti-infective vaccines market. Moreover, growing awareness for infectious disease diagnosis, increasing health consciousness, advancements in medical technology, thriving demands for control on infectious diseases are some other factors expected to flourish the growth of global anti-infective vaccines market. However, unavailability of anti-infective vaccines in some Report Description Report Description underdeveloped regions and high prizes of immunization can be the hurdles in the growth of global anti-infective vaccines market. Anti-infective vaccines Market: Segmentation The global anti-infective vaccines market has been segmented on the basis of product type, disease type end users and geography. Based on product type, the global anti-infective vaccines market is segmented into following: • Live/attenuated Vaccines • Inactivated Vaccines • DNA & recombinant vector Vaccines • Others (subunit, conjugate, toxoid vaccines) Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb1353 Based on disease type, the global anti-infective vaccines market is segmented into following: • Bacterial diseases • Typhoid Vaccines • Tuberculosis Vaccines • Tetanus & Diphtheria Vaccines • Others (anthrax, plague etc.) Report Description Report Description • • • • • Viral Diseases Influenza Vaccines Hepatitis Vaccines Polio Vaccine Others (rabies, zoster etc.) Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1353 Based on the distribution channel, the global anti-infective vaccines market is segmented into the following: • Hospitals Clinics • Public Hospitals • Private Clinics • Retail Pharmacies and Drug Stores • e-commerce Anti-infective vaccines Market: Overview The global anti-infective vaccines market possesses a high growth potential owing to ongoing researches and studies by government as well as research institutes for the development of prophylactic vaccines for various infectious diseases. Market for viral diseases vaccines is likely to hold major share in global anti-infective vaccines market due to threat of treating the disease. Report Description Report Description Government vaccination centers end user segment majorly contributes to the global antiinfective vaccines market volume due to strong patient pool towards national immunization programs. Anti-infective vaccines Market: Regional Wise Outlook Geographically, the global anti-infective vaccines market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America anti-infective vaccines market is estimated to lead the global anti-infective vaccines market due to existence of highly planned healthcare reimbursement schemes and higher purchasing power for expensive vaccines. Additionally, APAC and MEA anti-infective vaccines market are expected to grow rapidly during the forecast period because of rising national healthcare expenditure and urge to prevent the spread of infectious diseases Anti-infective vaccines Market: Key Players Some of the major players in the global anti-infective vaccines market are Barr Labs, Inc., Emergent BioDefense Operations Lansing Inc., Organon Teknika Corp LLC, Sanofi Pasteur, Inc., GlaxoSmithKline Biologicals, Merck & Co, Inc., CSL Limited, MedImmune LLC, ID Biomedical Corp., Novartis Vaccines and Diagnostics Limited, Protein Sciences Corporation, Intercell Biomedical, Wyeth Pharmaceuticals, Inc., MassBiologics, Berna Biotech, Ltd. and others. Numerous companies such as GlaxoSmithKline Pharmaceuticals Ltd., VaxGen etc. are engaged in the development of HIV vaccines which are expected to launch in near future. Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Customized Research Syndicated Research Investment Research Social Media Research Sector Coverage Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Healthcare, Pharmaceuticals & Medical Devices Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Social Media Research Hari. T (Sr. Manager - Global Business Development) Email: hari.t@futuremarketinsights.com Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Thank You! To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: sales@futuremarketinsights.com For other queries contact: Future Market Insights 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705
Similar documents
Pediatric Vaccines Market Size, Analysis, and Forecast Report: 2016-2026
Vaccination is a technique by which person is made immune or resistant to an infectious disease. Vaccination has saved millions of lives including adults, children, and animals, providing them a better quality and healthier life from various microorganism such as virus and bacteria. This is one of the most important reason behind the growth of this market. Vaccines stimulate the body's own immune system to protect the person against subsequent infection or disease. Vaccines are generally segmented into two target markets, adult and pediatric. Pediatric vaccines are commonly used for the immunization of children and adolescents against various various infectious diseases, like diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases.
Now Available: Meningococcal Vaccines Market Forecast and Growth 2016-2026
Meningococcal disease is a potentially fatal illness caused due to bacterium known as Neisseria meningitides. The bacteria is known to cause serious infection in the meninges, which are thin layers of connective tissues surrounding the brain and spinal cord. Common clinical symptoms of meningococcal disease are meningitis, bacteremia, and pneumonia. Other less common indications include myocarditis, endocarditis or pericarditis, arthritis, conjunctivitis, urethritis, pharyngitis, and cervicitis. Symptoms associated with these disease include high fever, neck stiffness, confusion, nausea, vomiting, lethargy, and petechial rashes.
Meningococcal vaccines are known to be found on the World Health Organization’s List of Essential Medicines. The bacteria can be classified into over 10 serotypes based in their immunologic reactivity. Currently, globally marketed meningococcal vaccines are of four types - polysaccharide-based, bivalent (Serogroup A and C), trivalent (Serogroup A, C and W-135), and tetravalent (Serogroup A, C, Y and W-135). There is currently only one vaccine available for Serogroup B in the US, while it account for over one-third of the disease cases in the country. The nature and components of the vaccines are purified, heat-stable, lyophilized capsular polysaccharides derived from the meningococci of the respective serogroups.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1252
Disease epidemiology of the meningococcal disease has undergone a radical change over the last century. Case-fatality ratios have witnessed a decline of from a high of 70% in the first part of the twentieth century to less than 15% after 2000. Of late the disease caused by Serogroup Y has increased from prevalence rate of 2% to over 35% between 1990 and 2005. The disease is contractible in nature primarily through antimicrobial chemoprophylaxis. There are currently three meningococcal vaccines available in the US to prevent this life-threatening disease. However, these vaccines frequently feature under the list of critical drugs in shortage.
Meningococcal Vaccines Market: Drivers and Restraints
The primary driver of meningococcal vaccines are introduction of advanced serotype B vaccines from large global drugmakers such as Novartis and Pfizer. The expansion of routine immunization programs across all parts of the world is much needed for the commercial success of these vaccines. Increase in funding from the government of compulsory immunizations at birth will also reduce out-of-pocket expenses of patients and increase affordable access to meningitis vaccines. Further, higher annual meningococcal disease incidence among infants and healthy young adults also is likely to encourage use of the vaccine.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1252
The prime barriers of the market include price wars for the vaccines from comparable drugmakers that may wipe out a greater customer base and reduce overall customer coverage. The other barrier includes increasing financial austerity in the European nations, which is expected to hamper the R&D base for the vaccines. Further, serotype mismatch and less than optimum coverage across countries is likely to negatively affect the demand for the vaccines. A delay in assessing the disease epidemiology over regular intervals due to cost issues may negatively impact the market for meningococcal vaccines over the long-term in the developing nations.
Meningococcal Vaccines Market: Segmentation
Global Compression Therapy Devices is further segmented into these following types:
By Product Type
• Monovalent
• Bivalent
• Trivalent
• Tetravalent or Quadrivalent
By formulation
• Polysaccharide-based
• Conjugate-based
• Combination-based
By indication
• Pneumonia
• Meningitis
• Bacteremia
• Others (arthritis, conjunctivitis, Urethritis)
Meningococcal Vaccines Market: Overview
With the advancement of research and development, increase in awareness of disease incidence and increasing government support in routine immunizations the meningococcal vaccines Market is gaining traction as a treatment of choice among patients. This market is expected to grow at a healthy CAGR in the forecast period (2015-2025).
Browse full report: http://www.futuremarketinsights.com/reports/meningococcal-vaccines-market
Rising prophylactic vaccination among infants, who tend to cover the largest endemic population are expected to drive the market in the forecast period.
Meningococcal Vaccines Market: Region-wise Outlook
Depending on geographic regions, global compression therapy market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
In terms of geography, North America dominates the Meningococcal Vaccines Market market, followed by Europe. Growing aging population and increasing prevalence of diabetes are also supporting the growth of compression therapy market in this regions. India, China, and Japan are expected to be the fastest-growing markets for compression therapy in Asia.
Meningococcal Vaccines Market: Key Players
Some of the key players in compression therapy market are GlaxoSmithKline PLC, JN-International Medical Corporation, Novartis International AG, Sanofi SA, Pfizer, Inc. and Baxter International, Inc
